Stock Financial Ratios


VRAY / ViewRay, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price9.44
Volume277,800.00
Market Cap ($M)562.26
Enterprise Value ($M)221.16
Book Value ($M)-43.65
Book Value / Share-1.09
Price / Book-21.16
NCAV ($M)11.54
NCAV / Share0.29
Price / NCAV13.77
Income Statement (mra) ($M)
Revenue22.24
EBITDA-44.17
Net Income-50.64
Balance Sheet (mrq) ($M)
Cash & Equivalents34.41
Cash / Share0.86
Assets88.13
Liabilities114.71
Quick Ratio0.75
Current Ratio0.97
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-79.49
Return on Assets (ROA)-1.04
Return on Equity (ROE)1.16
Identifiers and Descriptors
CUSIP92672L107
Central Index Key (CIK)1597313
Industry Groups
SIC 3845 - Electromedical and Electrotherapeutic Apparatus
Share Statistics
Common Shares Outstanding (M)67.45
Scoring Models
Piotroski F Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Inventory Per Share0.46
Treasury Stock Per Share0.00
Property Plant And Equipment Per Share0.28
Property Plant And Equipment Gross Per Share0.62
Long Term Debt Per Share1.11
Deferred Income Tax Liabilities Per Share0.00
Debt Per Share1.11
Liabilities Current Per Share1.19
Assets Other Non Current Per Share0.00
Liabilities Other Non Current Per Share0.16
Intangibles Per Share0.00
Goodwill Per Share0.00
Liabilities Per Share2.86
Minority Interest Per Share0.00
Retained Earnings Per Share-7.37
Current Portion Of Long Term Debt Per Share0.00
Cash And Equivalents Per Share0.86
Inventory Raw Materials Per Share0.00
Liabilities And Stock Equity Per Share2.20
Assets Other Current Per Share0.00
Accounts Payable Per Share0.00
Inventory Finished Goods Per Share0.00
Additional Paid In Capital Per Share6.69
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Assets Current Per Share1.88
Equity Per Share-0.66
Accumulated Depreciation And Depletion Per Share0.34
Assets Per Share2.20
Property Plant And Equipment Net Per Share0.28
Cash Per Share0.86
Inventory Work In Progress Per Share0.00
Accounts Receivable Per Share0.03

Related News Stories

Earnings Review and Free Research Report: Natus Medical’s Revenue Soared 34.9%

2017-11-22 accesswire
LONDON, UK / ACCESSWIRE / November 22, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Natus Medical Inc. (NASDAQ: BABY), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=BABY, following the Company's reporting of its third quarter fiscal 2017 operating results on October 25, 2017. The maker of medical device for newborn care outperformed top- and bottom-line expectations. (25-0)

BRIEF-ViewRay Q3 loss per share $0.19

2017-11-13 reuters
* ViewRay - ‍total backlog grew to $194.8 million, as of September 30, 2017, up from $125.2 million as of September 30, 2016​ (5-0)

Major Institutional Investors Buy ViewRay Stock

2017-10-31 seekingalpha
In the current Wall Street climate of ultra-bullish investing, some companies seem to be attracting a lot of attention despite dubious performance, while others are firing on all cylinders and failing to gain favor from investors; neither of these cases apply to ViewRay, Inc. (NASDAQ:VRAY). (5-0)

BRIEF-ViewRay raises aggregate gross proceeds of about $50 mln through sale of stock in direct registered offering.​

2017-10-25 reuters
* ViewRay Inc -‍ raised aggregate gross proceeds of about $50 million through issuance and sale of 8.4 million shares of its stock in direct registered offering.​ Source text for Eikon: Further company coverage: (5-0)

Biotech Forum Daily Digest: Spotlighting Ignyta's Big Recent Rally

2017-10-19 seekingalpha
While the main biotech indices are holding up well despite minor losses, sentiment on some smaller 'Tier 3' concerns seems to be noticeably weakening. (311-1)

CUSIP: 92672L107